KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 55 filers reported holding KALA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $20,000 | -88.0% | 67,015 | -44.1% | 0.00% | – |
| Q1 2022 | $166,000 | +654.5% | 119,963 | +552.8% | 0.00% | – |
| Q4 2021 | $22,000 | -63.9% | 18,376 | -21.1% | 0.00% | – |
| Q3 2021 | $61,000 | -91.1% | 23,300 | -82.0% | 0.00% | – |
| Q2 2021 | $687,000 | -44.7% | 129,644 | -29.7% | 0.00% | – |
| Q1 2021 | $1,243,000 | +25.8% | 184,383 | +26.5% | 0.00% | – |
| Q4 2020 | $988,000 | +80.6% | 145,800 | +99.9% | 0.00% | – |
| Q3 2020 | $547,000 | -43.8% | 72,953 | -21.3% | 0.00% | – |
| Q2 2020 | $974,000 | +98.8% | 92,738 | +66.5% | 0.00% | – |
| Q1 2020 | $490,000 | – | 55,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,333,333 | $5,073,000 | 100.00% |
| CAXTON CORP | 1,483,343 | $5,644,000 | 6.36% |
| Polaris Venture Management Co. V, L.L.C. | 1,197,032 | $4,555,000 | 2.59% |
| RA Capital Management | 4,537,478 | $17,265,000 | 1.03% |
| Orbimed Advisors | 3,447,840 | $13,119,000 | 0.25% |
| Matisse Capital | 46,500 | $177,000 | 0.22% |
| PURA VIDA INVESTMENTS, LLC | 332,831 | $1,266,000 | 0.22% |
| Sofinnova Investments, Inc. | 478,206 | $1,819,000 | 0.16% |
| HARBOURVEST PARTNERS LLC | 99,186 | $377,000 | 0.16% |
| ALGERT GLOBAL LLC | 47,195 | $180,000 | 0.07% |